An update on emerging drugs for asthma

Expert Opinion on Emerging Drugs

Volumn 17, Issue 1, 2012, Pages 37-42

  Walsh, Garry M ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

asthma; IL 13; IL 4; IL 5

Indexed keywords

AMG 317; BENRALIZUMAB; CYTOKINE RECEPTOR ANTAGONIST; ETANERCEPT; GLUCOCORTICOID; GOLIMUMAB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; INTERLEUKIN 13; INTERLEUKIN 13 RECEPTOR ALPHA1; INTERLEUKIN 4; INTERLEUKIN 4 RECEPTOR ALPHA; INTERLEUKIN 5; INTERLEUKIN 5 RECEPTOR ALPHA; LEBRIKIZUMAB; MEPOLIZUMAB; PITRAKINRA; PLACEBO; PREDNISONE; RESLIZUMAB; STAT6 PROTEIN; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR RUNX2; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ASTHMA; BASOPHIL; BLOOD EXAMINATION; BRONCHUS HYPERREACTIVITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHURG STRAUSS SYNDROME; DISEASE CONTROL; DISEASE EXACERBATION; DRUG BINDING; DRUG EFFICACY; DRUG TARGETING; DRUG TOLERABILITY; EOSINOPHIL COUNT; EOSINOPHILIA; EOSINOPHILIC ESOPHAGITIS; EOSINOPHILIC NASAL POLYPOSIS; EXTRACELLULAR MATRIX; HUMAN; HYPEREOSINOPHILIC SYNDROME; INFECTION; INFLAMMATION; INNATE IMMUNITY; LUNG FUNCTION; MAST CELL; MUSCLE CELL; NOSE POLYP; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SHORT SURVEY; SPUTUM ANALYSIS; SPUTUM EOSINOPHILIA;

ANIMALS; ANTI-ASTHMATIC AGENTS; ASTHMA; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; HUMANS; INTERLEUKIN-13; INTERLEUKIN-4; INTERLEUKIN-5; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84858984498     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.2012.657625     Document Type: Short Survey

References (44)

1. Anandan C, Nurmatov U, van Schayck OC, Sheikh A. Is the prevalence of asthma declining? Systematic review of epidemiological studies. Allergy 2010;65(2):152-67
2. Barnes PJ. Pathophysiology of allergic inflammation. Immunol Rev 2011;242(1):31-50
3. Barnes PJ, Adcock IM, Ito K. Histone acetylation and deacetylation: importance in inflammatory lung diseases. Eur Respir J 2005;25:552-63 (Pubitemid 40331188)
4. Berger WE. New approaches to managing asthma: a US perspective. Ther Clin Risk Manag 2008;4:363-79 (Pubitemid 351711996)
5. Holtzman MJ. Drug development for asthma. Am J Respir Cell Mol Biol 2003;29:163-71 (Pubitemid 36936643)
6. Walsh GM. Targeting airway inflammation: novel therapies for the treatment of asthma. Curr Med Chem 2006;13:3105-11 (Pubitemid 44509711)
7. Walsh GM. Novel cytokine-directed therapies for asthma. Discov Med 2011;11(59):283-91
8. O'Byrne PM. The demise of anti IL-5 for asthma, or not. Am J Respir Crit Care Med 2007;176:1059-60 (Pubitemid 350223749)
9. Walsh GM. Mepolizumab and eosinophil-mediated disease. Curr Med Chem 2009;16:4774-8
10. Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009;360:973-84 This trial used patients with sputum eosinophilia whose asthma symptoms were refractory to high-dose GCs and who had greater than two exacerbations requiring oral GCs during the previous 12 months. The primary end point was the number of severe exacerbations per patient; secondary outcomes included asthma symptoms, HRQoL measured with the AQLQ, lung function, AHR and blood or sputum eosinophil count. Compared with placebo (n = 32), mepolizumab treatment (n = 29) resulted in a significant reduction in blood and sputum eosinophil numbers, with fewer severe exacerbations per patient compared with placebo, together with a significant improvement in HRQoL.
11. Nair P, Pizzichini MM, Kjarsgaard M, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 2009;360:985-93 Patients (n = 9 active, 11 placebo) with a history of exacerbations exhibited persistent sputum eosinophilia despite requiring oral prednisone for control of asthma symptoms. In the mepolizumab-treated group, 1 patient had an exacerbation compared with 12 exacerbations in the placebo group. Mepolizumab treatment significantly reduced sputum and blood eosinophil counts to normal values, yielded a significant reduction in the oral prednisone dose, a modest improvement in FEV1 (mean = 300 ml), significant improvement in scores on the Juniper Asthma Control Questionnaire (p = 0.01) and significant improvement in HRQoL with no significant side effects reported.
12. Kim S, Marigowda G, Oren E, et al. Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome. J Allergy Clin Immunol 2010;125:1336-43
13. Kahn JE, Grandpeix-Guyodo C, Marroun I, et al. Sustained response to mepolizumab in refractory Churg-Strauss syndrome. J Allergy Clin Immunol 2010;125:267-70
14. Castro M, Mathur S, Hargreave F, for the Res-5-0010 Study Group. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med 2011; [Epub ahead of print]
15. Walsh GM. Reslizumab, a humanized monoclonal anti-IL-5 antibody for the treatment of eosinophil-mediated inflammatory conditions. Curr Opin Mol Ther 2009;11:329-36
16. Kolbeck R, Kozhich A, Koike M, et al. MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol 2010;125:1344-53.e2
17. Busse WW, Katial R, Gossage D, et al. Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti - IL-5 receptor antibody, in a phase I study of subjects with mild asthma. J Allergy Clin Immunol 2010;125:1237-44 An open-label clinical trial demonstrating that single, escalating doses of benralizumab had a reasonable safety profile and resulted in marked reduction of peripheral blood eosinophil counts in patients with mild allergic asthma within 24 h of administration.
18. Blanchard C, Rothenberg ME. Biology of the eosinophil. Adv Immunol 2009;101:81-121
19. Barrett NA, Austen KF. Innate cells and T helper 2 cell immunity in airway inflammation. Immunity 2009;31(3):425-37
20. Wills-Karp M, Luyimbazi J, Xu X, et al. Interleukin-13: central mediator of allergic asthma. Science 1998;282:2258-60
21. Tliba O, Deshpande D, Chen H, et al. IL-13 enhances agonist evoked calcium signals and contractile responses in airway smooth muscle. Br J Pharmacol 2003;140:1159-62 (Pubitemid 38117418)
22. Deshpande DA, Dogan S, Walseth TF, et al. Modulation of calcium signaling by interleukin-13 in human airway smooth muscle: role of CD38/cyclic adenosine diphosphate ribose pathway. Am J Respir Cell Mol Biol 2004;31:36-42 (Pubitemid 38888037)
23. Chiba Y, Nakazawa S, Todoroki M, et al. Interleukin-13 Augments Bronchial Smooth Muscle Contractility with an Upregulation of RhoA Protein. Am J Respir Cell Mol Biol 2009;40(2):159-67
24. Kuperman DA, Huang X, Koth LL, et al. Direct effects of interleukin-13 on epithelial cells cause airway hyperreactivity and mucus overproduction in asthma. Nat Med 2002;8:885-9
25. Jiang H, Harris MB, Rothman P. IL-4/ IL-13 signalling beyond JAK/STAT. J Allergy Clin Immunol 2000;105:1063-70 (Pubitemid 30418781)
26. Berry MA, Parker D, Neale N, et al. Sputum and bronchial submucosal IL-13 expression in asthma and eosinophilic bronchitis. J Allergy Clin Immunol 2004;114:1106-927. Saha SK, Berry MA, Parker D, et al. Increased sputum and bronchial biopsy IL-13 expression in severe asthma. J Allergy Clin Immunol 2008;121:685-91 (Pubitemid 351323866)
27. Brightling CE, Symon FA, Holgate ST, et al. Interleukin-4 and -13 expression is co-localized to mast cells within the airway smooth muscle in asthma. Clin Exp Allergy 2003;33:1711-16 (Pubitemid 38005392)
28. Grunstein MM, Hakonarson H, Leiter J, et al. IL-13-dependent autocrine signaling mediates altered responsiveness of IgE sensitized airway smooth muscle. Am J Physiol Lung Cell Mol Physiol 2002;282:L520-8 (Pubitemid 34654657)
29. Holgate ST. Has the time come to rethink the pathogenesis of asthma? Curr Opin Allergy Clin Immunol 2010;10(1):48-53
30. Danahay H, Atherton H, Jones G, et al. Interleukin-13 induces a hypersecretory ion transport phenotype in human bronchial epithelial cells. Am J Physiol Lung Cell MolPhysiol 2002;282:L226-36 (Pubitemid 34654674)
31. Ahdieh M, Vandenbos T, Youakim A. Lung epithelial barrier function and wound healing are decreased by IL-4 and IL-13 and enhanced by IFN-gamma. Am J Physiol Cell Physiol 2001;281:C2029-38
32. Wenzel SE, Schwartz LB, Langmac EL, et al. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med 1999;160:1001-8 (Pubitemid 29442043)
33. Hashimoto S, Gon Y, Takeshita I, et al. IL-4 and IL-13 induce myofibroblastic phenotype of human lung fibroblasts through c-Jun NH2-terminal kinase-dependent pathway. J Allergy Clin Immunol 2001;107:1001-8 (Pubitemid 32523339)
34. Blease K. Therapeutics targeting IL-13 for the treatment of pulmonary inflammation and airway remodeling. Curr Opin Investig Drugs 2008;9:1180-4
35. Corren J, Lemanske RF, Hanania NA, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 2011; [Epub ahead of print] This clinical trial with the anti-IL-13 biologic lebrikizumab in patients with uncontrolled asthma despite inhaled GC therapy reported that patients with high pretreatment levels of serum periostin, a cellular matrix protein that is released by airway epithelial cells stimulated with IL-13, had greater and significant improvement in lung function following lebrikizumab treatment than did patients with low periostin levels.
36. Sidhu SS, Yuan S, Innes AL, et al. Roles of epithelial cell-derived periostin in TGF-beta activation, collagen production and collagen gel elasticity in asthma. Proc Natl Acad Sci USA 2010;107:14170-5
37. Takayama G, Arima K, Kanaji T, et al. Periostin: a novel component of subepithelial fibrosis of bronchial asthma downstream of IL-4 and IL-13 signals. J Allergy Clin Immunol 2006;118:98-104 (Pubitemid 43946467)
38. Walsh GM. Emerging drugs for asthma. Expert Opin Emerg Drugs 2008;13:643-53
39. Wenzel SE, Ind PW, Otulana BA, et al. Inhaled pitrakinra, an IL-4/IL- 13 antagonist, reduced exacerbations in patients with eosinophilic asthma. Ann Cong Eur Resp Soc 2010;36:abstract #P3980
40. Corren J, Busse W, Meltzer EO, et al. A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma. Am J Respir Crit Care Med 2010;181(8):788-96
41. Brightling C, Berry M, Amrani Y. Targeting TNF-alpha: a novel therapeutic approach for asthma. J Allergy Clin Immunol 2008;121:5-10
42. Wenzel SE, Barnes PJ, Bleecker ER, et al. A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. Am J Respir Crit Care Med 2009;179(7):549-58 This clinical trial with the anti-TNF-a biologic golimumab in patients with severe uncontrolled persistent asthma reported negative clinical findings. Importantly, this trial was terminated early due to unacceptable adverse events, including frequent serious infections and eight malignancies in the active-treatment group compared with the placebo group.
43. Matera MG, Calzetta L, Cazzola M. TNF-alpha inhibitors in asthma and COPD: we must not throw the baby out with the bath water. Pulm Pharmacol Ther 2010;23(2):121-8
44. Holgate ST. A look at the pathogenesis of asthma: the need for a change in direction. Discov Med 2010;9(48):439-47